The Alpha-1 Project
Accelerating Therapeutic Development
The Alpha-1 Project (TAP) is uniquely qualified to support new drug discovery and development in Alpha-1. TAP directly invests in and supports pharmaceutical and biotech companies with highly promising compounds and devices that have the ability to eradicate the effects of liver disease and COPD caused by Alpha-1. This funding helps bridge the gap between basic academic research and the development of new drug targets and devices to find therapies and cures for Alpha-1. TAP leverages its investments by inviting pharmaceutical and biotech companies to participate in its projects. The resulting catalytic capital helps get these promising therapies and devices through clinical trials and into commercialization.
Our investment agenda for TAP is driven by members of our Scientific and Business Advisory Council and has focused on highly promising therapies that need additional funding and support to complete clinical trials. To date, TAP has Invested in 12 therapies directly targeting Alpha-1, and 4 tools that assist in the therapeutic development process.
What is TAP?
TAP is a wholly-owned subsidiary of the Alpha-1 Foundation, Inc., singularly focused on investing in highly promising drug therapies and devices that can eliminate the effects of liver disease and COPD caused by Alpha-1 Antitrypsin Deficiency. The actions of TAP are guided by its vision. Click here to view the brochure
To create a world without the effects of COPD and liver disease caused by Alpha-1 Antitrypsin Deficiency.
Making a Difference Today
TAP is singularly focused on making a positive difference in the lives of people suffering from liver disease or COPD caused by Alpha-1. Of the twelve therapeutic development programs we’ve funded, five are in active clinical trials as of Fall 2022, and another is in the pre-clinical stage.
Part of what makes us unique is our focused approach. This focus allows TAP to keep administrative costs to a minimum and to put more of our resources directly to work developing cures and therapies.
Contact TAP today to see how we are making a difference!
